Does Your List Of Penny Stocks Have These Names On It?
When it comes to penny stocks to buy, I’m sure you’ve got your strategies to pick the best. In addition to a personal strategy, many investors look to the analysts to see what they think about certain stocks. Believe it or not, stocks under $5 are covered by many different analysts. These aren’t just from boutique firms but actual, popular investment banks as well.
- 5 Strategies To Make Anyone A More Profitable Trader
- Beginner’s Guide To Trading Penny Stocks in 2020
One thing to keep in mind, however, is that analysts aren’t the “end all, be all”. Keep in mind that they are people too. Emotions can play a role with analysts just as they can with retail investors. While most keep that factor outside of their analysis, other topics might also sway certain analysts in certain directions.
Let’s look at a broad example. Personally, I’ve been looking at gold stocks recently. The main reason is that the stock market in general is volatile. During times like this, gold tends to move higher. In light of this, gold and gold penny stocks can push higher without corporate catalysts in play; simply sector momentum.
Penny Stocks And Analyst Ratings
When it comes to gold penny stocks, many of the companies saw analysts upgrade and boost price targets for certain companies. In this case, just a few days ago we saw gold stocks plummet. That was at the same time those same stocks received their upgrades. So, were the analysts wrong? Not necessarily but that answer has more to do with the analysts and their overall outlook for the stocks.
Simply put, just because an analyst puts a price target or rating on certain penny stocks, doesn’t mean it will happen overnight. It’s up to investors to take these ratings into consideration but move on to more research beyond just this information to arrive at a decision of whether to avoid or buy penny stocks in a given sector. With this in mind, let’s see what analysts had to say about these companies recently.
Penny Stocks To Buy [ According to Analysts]: Capricor Therapeutics
Shares of Capricor Therapeutics (CAPR Stock Report) have been on the radar since late March. At the time CAPR stock was trading around $1.60 and the company was about to host a key opinion leader presentation. The penny stock ended up jumping to highs of $2.25 and settled out around $1.75 during the weeks to follow.
At the end of April, CAPR stock made its biggest move yet and rallied to highs of $11.08. This came after the company announced new data reporting 100% survival in critical COVID-19 patients who were treated with Capricor’s lead asset, off-the-shelf cardiac cell therapy CAP-1002. This was at Cedars-Sinai Medical Center as part of six compassionate care cases.
However, like many penny stocks that make moves like this, CAPR fell back almost immediately afterward. Heading into the first week of June, this could be one of the top penny stocks to watch after the company’s latest industry presentation. This past week Capricor presented at Maxim Group’s COVID-19 Virtual Conference.
CEO, Linda Marbán, Ph.D, participated on the panel “Cell therapy for ARDS – When Remdesivir is not enough.” During the late afternoon on May 29 CAPR stock managed to see its first green close after 4 consecutive down days in the market. As far as analysts are concerned, the average rating shows “Strong Buy” right now for CAPR stock.
Penny Stocks To Buy [ According to Analysts]: Genius Brands International Inc.
Genius Brands International Inc. (GNUS Stock Report) has been at the top of the list of penny stocks to watch this month. If you’ve been following the trend with this stock, shares dipped late last week. This came as the company announced a discounted share offering during a mid-day session.
Considering that this raise wasn’t just for “corporate purposes,” GNUS stock managed to mount a reversal in this brief downtrend. Genius said net proceeds will be used to grow its newly-announced digital network for children, Kartoon Channel!. It will also fund the production of additional episodes of its series Rainbow Rangers, and repay certain outstanding debt.
Since late-January GNUS stock has been closely followed on our site. At the time, shares traded around $0.40. This week the stock reached a high of $2.82; not bad for a few weeks of momentum. But could the best be yet to come? GNUS stock continued to steadily head higher during afterhours trading on Friday. Furthermore, among analysts the average rating for GNUS stock shows a “Strong Buy” as of this article. Will it be one of the top penny stocks to watch in June?
Penny Stocks To Buy [ According to Analysts]: ADMA Biologics Inc.
ADMA Biologics Inc (ADMA Stock Report) caught another boost of action on Friday. The company is set to participate in the Jefferies Virtual Healthcare Conference on June 2. Adam Grossman, President, and Chief Executive Officer will participate in a fireside chat at the conference. If you remember, ADMA stock was on the list starting in March. At the time it was trading around $3. But that Jefferies news wasn’t the only reason heads turned on Friday.
This Sunday, 60 Minutes will air a timely feature related to COVID-19. Traders circulated this information on Friday and it triggered a rally in ADMA stock. This weekend the news show will air a spot titled “The Promise Of Plasma”. Anchor, Bill Whitaker reports on how doctors are taking the blood plasma of COVID-19 survivors, and the virus-fighting antibodies in it, to create the life-saving therapy.
This comes just after ADMA’s latest news. The company announced it has begun collecting convalescent plasma through its wholly-owned subsidiary, ADMA BioCenters Georgia Inc. The plasma was from individuals who have recovered from COVID-19. ADMA is an end-to-end commercial biopharmaceutical company.
It focuses on manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection. Obviously this could be a catalyst to pay attention to if ADMA is on your list of penny stocks. According to analysts, ADMA Biologics has an average “Strong Buy” rating as of this article. Will it head higher at the start of June 2020?